Advance in the research of vaccines for treating malignant lymphomas

Currently,some types of malignant lymphoma(ML) still can not be cured by chemotherapy or radiotherapy,such as indolent lymphoma.Immunotherapy has now become an important part in therapies of hematologic malignancies.Several monoclonal antibodies have been approved by the FDA and are in widespread use for ML.ML is composed of clonal proliferation of lymphocytes.The variable regions of the immunoglobulin are expressed on the surface of malignant B cells,and the T cell receptor(TCR) on the surface of malignant T cells.These regions are idiotype(Id) which can serve as a tumor-specific marker for the malignant clone.Idiotype is the basis of the produce and efficacy of ML vaccines.Lots of basic and clinical studies for different ML vaccines have been performed to find out a radical regimen for ML.Protein vaccine had finished Ⅲ clinical trial and the results showed primary effect.Different kinds of secondary vaccines were in study and clinical trial.This article reviewed the advance in the research of vaccines for treating malignant lymphomas.